The NHS Funding Crisis and What It Means for Your Pharmacy
NHS pharmacy funding has fallen in real terms for a decade. Here's what the numbers mean and how private PGD services can fill the gap.
The financial reality facing UK community pharmacy is stark. NHS funding has not kept pace with inflation, costs have risen sharply, and the traditional dispensing model is under pressure from multiple directions.
The numbers tell the story. The Community Pharmacy Contractual Framework (CPCF) delivered a funding settlement that many pharmacy bodies have described as inadequate. When adjusted for inflation, real-terms funding per pharmacy has declined consistently over the past decade. The average independent pharmacy now operates on margins that would be unsustainable in most other healthcare settings.
Meanwhile, costs have risen. Energy bills, staff wages (following National Living Wage increases), drug tariff fluctuations, and property costs have all increased. The Pharmaceutical Services Negotiating Committee (PSNC) has repeatedly highlighted the growing gap between what pharmacies receive and what it costs to operate.
Dispensing volume — historically the core revenue driver — is under structural pressure. Repeat dispensing hubs, online pharmacies, and GP-direct dispensing are all reducing footfall. The number of pharmacies in England has been declining year on year.
Against this backdrop, private clinical services under PGD represent one of the most viable diversification strategies available to community pharmacy.
The revenue potential is significant. A pharmacy offering a comprehensive PGD service portfolio — travel health, weight management, vaccines, sexual health, women's health — can generate £50,000 or more per year in private service revenue. This is net new income, not a reallocation of existing NHS fees.
Critically, private PGD services carry no per-item clawback risk, no drug tariff exposure, and no Category M uncertainty. The pharmacy sets the price, delivers the service, and keeps the revenue. The only cost is the PGD provider subscription and the pharmacist's time — which is already being paid for.
The pharmacies that thrive in the current funding environment will be those that build sustainable private revenue streams alongside their NHS contract. PGD services are not a replacement for NHS income — they're the growth engine that makes the overall business model viable.
This is not a theoretical argument. The pharmacies already offering comprehensive PGD services are the ones reporting stable or growing total revenue, while those relying solely on NHS dispensing are facing the squeeze.
Want to offer these services?
Get Real Health provides 60+ PGDs, built-in training, and a consultation platform — all for one flat annual fee. No per-consult charges.